FOLH1 and renal cell carcinoma: Udovicich et al. evaluated PSMA PET/CT in a retrospective cohort of 61 metastatic RCC patients and found that the sensitivity was 91% (95% CI 77–98%) for both PSMA PET/CT and CT, which differed from other studies.